SZT2 Inhibitors
Chemical inhibitors of SZT2 can disrupt the protein's function by targeting the mTOR signaling pathway, with which SZT2 is associated. Rapamycin, for example, binds to and inhibits mTOR, a central component of mTORC1, thus leading to the functional inhibition of SZT2. Similarly, Torin 1 and PP242 are ATP-competitive inhibitors that directly inhibit both mTORC1 and mTORC2 complexes, resulting in diminished SZT2 function due to the protein's involvement in mTORC1 signaling. Ku-0063794 and AZD8055 also inhibit mTOR activity, which in turn decreases mTORC1 signaling and thereby inhibits the function of SZT2. WYE-125132, another ATP-competitive inhibitor, selectively targets mTOR to achieve the same effect on SZT2 function. These inhibitors work by directly interfering with the kinase activity of mTOR, a critical regulator of cell growth and metabolism that SZT2 is known to interact with.
In addition to these mTOR-focused inhibitors, SZT2 function can also be disrupted by compounds that inhibit PI3K, an upstream regulator of the mTOR pathway. LY294002 and Wortmannin are PI3K inhibitors that, by suppressing PI3K activity, lead to a downstream reduction in mTORC1 signaling, which in turn functionally inhibits SZT2. Palomid 529, although not a direct inhibitor of mTOR, disrupts the mTOR/Akt pathway, and indirectly diminishes SZT2 function, as it is part of the mTORC1 complex. PF-04691502, a dual PI3K/mTOR inhibitor, effectively hampers mTORC1 signaling by inhibiting both the upstream PI3K and mTOR itself, leading to the functional inhibition of SZT2. ZSTK474, another PI3K inhibitor, likewise reduces the activation of mTORC1, impacting SZT2's function. KU-0068650, like other potent mTOR inhibitors, reduces mTORC1 activity and thereby inhibits SZT2.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), which SZT2 interacts with as part of the mTORC1 complex. Inhibition of mTOR leads to decreased mTORC1 signaling, which is necessary for SZT2-mediated regulation of neuronal excitability and synaptic function, resulting in the functional inhibition of SZT2. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 directly inhibits mTORC1 and mTORC2 complexes. Since SZT2 is associated with mTORC1 signaling, inhibition of mTORC1 by Torin 1 would disrupt SZT2's function in the pathway, leading to its functional inhibition. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR. By inhibiting mTOR kinase activity, PP242 impairs the function of mTORC1, with which SZT2 is associated, thereby functionally inhibiting SZT2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and since PI3K signaling is upstream of mTOR, its inhibition can reduce mTORC1 activity. This reduction in mTORC1 activity would subsequently lead to functional inhibition of SZT2, as SZT2 is part of the mTORC1 signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and it works similarly to LY294002. By inhibiting PI3K, Wortmannin would decrease mTORC1 signaling and functionally inhibit SZT2, which is involved in mTORC1 signaling. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
Ku-0063794 is an inhibitor of both mTORC1 and mTORC2. Inhibition of these complexes would lead to a decrease in mTOR signaling, thus inhibiting SZT2 function due to the protein's association with mTORC1. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) inhibits the mTOR/Akt pathway. By inhibiting this pathway, P529 indirectly inhibits the function of SZT2, as it is part of mTORC1 signaling. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR kinases. By targeting mTOR, AZD8055 would inhibit mTORC1 and mTORC2 signaling, resulting in the functional inhibition of SZT2 due to its role in mTORC1 signaling. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a PI3K inhibitor, and by inhibiting PI3K, it would lead to decreased activation of mTORC1. This would functionally inhibit SZT2, which is involved in mTORC1 signaling. | ||||||
WYE-125132 | 1144068-46-1 | sc-364651 sc-364651A | 10 mg 50 mg | $510.00 $1536.00 | ||
WYE-125132 is a highly selective ATP-competitive inhibitor of mTOR. By selectively inhibiting mTOR, WYE-125132 would decrease mTORC1 signaling, leading to the functional inhibition of SZT2, which is associated with the mTORC1 pathway. | ||||||